Regressive effect of intralesional injection of a moderate dose of recombinant interleukin-2 on carcinoma erysipeloides from gastric carcinoma.
Cutaneous metastatic diseases remain nearly incurable and a major medical challenge. It has been shown that interleukin-2 (IL-2) has potential as a therapeutic agent for various neoplastic diseases such as melanoma, renal cell carcinoma and myeloid leukaemia. However, IL-2 therapy for metastatic skin lesions has not been established yet. In the present study, we investigated the effect of recombinant IL-2 in a 79-year-old Japanese man with carcinoma erysipeloides, a rare type of cutaneous metastasis from gastric cancer. He was treated with an intralesional injection of rIL-2 (200 000 JRU) daily. Ten days after treatment, an erythematous plaque was eliminated almost completely leaving light brown pigmentation. A skin biopsy from the pigmented area revealed the absence of obvious tumour cells. These findings suggest that this cytokine should be considered for the clinical treatment of several inoperative metastatic cutaneous diseases, including gastric cancer.
Hamamoto
Y
Y
Department of Dermatology, Yamaguchi University School of Medicine, Japan.
Nagai
K
K
Ichimiya
M
M
Yamamoto
K
K
Kinoshita
E
E
Muto
M
M
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy / Q000379:methods; D017809:Fatal Outcome; D006801:Humans; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary*; D013274:Stomach Neoplasms
D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins